SAN RAFAEL, California, August 5, 2024 — Biomarin has announced that it will limit commercial, research and manufacturing programs for its factor VIII gene therapy...
CLICK HERE to access the 2024 ISSUE TWO of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...
PREAMBLE We have already come to the end of this important series of articles about the national board and operational committees on which our volunteers...
PREAMBLE In our special series of articles on the numerous committees our volunteers sit on, it is our pleasure to now present you the International...
PREAMBLE In our special series of articles on the numerous committees our volunteers sit on, it is our pleasure to now present you the latest...
